Clinical trials · Texas
Locally Advanced or Metastatic Solid Tumors clinical trials in Texas
We’re tracking 669 recruiting locally advanced or metastatic solid tumors studies with a site in Texas — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in Texas
- NCT05748834RecruitingPhase 2
Tucatinib plus Doxil for HER2-positive metastatic breast cancer
This Phase 2 study tests tucatinib (a HER2-targeted pill) plus Doxil (a chemotherapy medicine) to slow or shrink HER2-positive metastatic breast cancer that has been treated before. It may help by targeting HER2 cancer cells more effectively than past treatments alone.
San Antonio, TexasAges 18 years+ - NCT05931393RecruitingPhase 2
Cabozantinib retreatment after it helped, in kidney cancer study
This Phase 2 study tests a “next-step” cabozantinib strategy for advanced kidney cancer (RCC) after your cancer previously responded to cabozantinib and then progressed. It aims to see if re-using cabozantinib in a planned sequence can control the cancer again with manageable side effects.
Dallas, TexasAges 18 years+ - NCT06031688RecruitingPhase 2
Targeted treatment for lung cancer with a MET gene change
This trial tests a targeted drug for advanced non-small cell lung cancer that has a specific genetic change called MET exon 14 skipping. It aims to see if the drug can shrink tumors or slow the cancer's growth, and may help people who have or haven't had prior treatment.
Amarillo, TexasAges 18 minutes+ - NCT06034275RecruitingPhase 1
Study of VIP943 for CD123-positive blood cancers
This trial tests a new drug called VIP943 for people with advanced acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL), or myelodysplastic syndrome (MDS) whose cancer cells have a marker called CD123. It is for those who have tried all other treatments or cannot receive them.
Houston, TexasAges 18 years+ - NCT06050733Recruiting
Gut bacteria and immunotherapy response in solid tumors
This study looks at how the bacteria in your gut may affect how well immunotherapy works for solid cancers that have spread or cannot be removed. It focuses on people who have been on certain immunotherapy drugs (PD-1 or PD-L1 inhibitors) for at least 3 months but less than 2 years.
Galveston, TexasAges 35–75 - NCT06053658RecruitingPhase 2
Tivozanib and Nivolumab for advanced kidney cancer
This trial tests a combination of two drugs (tivozanib and nivolumab) for people with advanced kidney cancer that is not clear cell type. It aims to see if this drug pair can shrink or slow the cancer.
Houston, TexasAges 18 years+ - NCT06236438RecruitingPhase 2/Phase 3
Livmoniplimab plus budigalimab and chemo for untreated lung cancer
This trial tests a new combination of two immune system drugs (livmoniplimab and budigalimab) plus standard chemotherapy compared to the current standard treatment (pembrolizumab plus chemo) for people with advanced non-small cell lung cancer that has not been treated yet. The goal is to see if the new combination works better at controlling the cancer.
El Paso, TexasAges 18 years+ - NCT06266338RecruitingPhase 2
Pembrolizumab and lenvatinib for recurrent or metastatic cervical cancer
This study tests a combination of two drugs, pembrolizumab (an immunotherapy) and lenvatinib (a targeted therapy), for people with cervical cancer that has come back or spread. The goal is to see if this drug combination can shrink tumors or slow the cancer's growth.
Dallas, TexasAges 18 years+ - NCT06282575RecruitingPhase 3
Zanidatamab plus chemo for advanced HER2-positive bile duct cancer
This phase 3 trial tests whether adding zanidatamab (a targeted antibody) to standard chemotherapy can improve outcomes for advanced HER2-positive biliary tract cancer. If you have this type of cancer that has spread or can't be removed, and you've had little or no prior treatment, this study might be an option.
Dallas, TexasAges 18 years+ - NCT06422143RecruitingPhase 3
Keytruda with or without Sac-TMT for advanced squamous lung cancer
This trial tests the combination of pembrolizumab (Keytruda) with or without a new drug, sacituzumab tirumotecan (Sac-TMT), as initial treatment for advanced squamous non-small cell lung cancer. It aims to see if adding Sac-TMT after initial treatment helps keep cancer under control longer.
Houston, TexasAges 18 years+ - NCT06345729RecruitingPhase 3
Study of Calderasib and Pembrolizumab for Advanced Lung Cancer
This trial tests a new combination of two drugs (Calderasib and Pembrolizumab) in people with a specific type of advanced lung cancer (non-small cell lung cancer) that has a KRAS G12C mutation and high PD-L1 levels. It aims to see if this treatment can help shrink or control the cancer.
Houston, TexasAges 18 years+ - NCT06409065Recruiting
Emotional and spiritual support for advanced cancer and caregivers
This study offers a program to help people with advanced cancer and their caregivers cope with emotional and spiritual distress. It involves talking with a counselor together to improve your well-being.
Houston, TexasAges 18 years+ - NCT06420206Recruiting
Goals of care discussion in the ER for advanced cancer
This study is for people with advanced lung or GI cancer who come to the emergency room at MD Anderson. It’s testing a conversation to help you and your doctor discuss your goals and wishes for care.
Houston, TexasAges 18 years+ - NCT06448026RecruitingPhase 2
Cemiplimab and cetuximab before surgery for mouth or throat cancer
This trial tests whether combining two targeted drugs (cemiplimab and cetuximab) before surgery can help people with recurrent mouth or throat cancer that has come back after initial treatment. It aims to see if this approach makes surgery more effective.
Houston, TexasAges 18 years+ - NCT05482893RecruitingPhase 1/Phase 2
Spevatamig for advanced stomach, pancreas, or bile duct cancer
This trial tests a new drug called Spevatamig (PT886), alone or with different chemotherapy and/or immunotherapy combinations, for people with certain advanced stomach, pancreatic, or bile duct cancers. The goal is to see if it shrinks tumors and is safe.
Houston, TexasAges 18 years+ - NCT07315113RecruitingPhase 1
Study of NXP900 plus osimertinib for EGFR lung cancer
This trial tests a new study drug called NXP900 combined with the targeted therapy osimertinib for people with advanced EGFR-mutated lung cancer who have already been treated with osimertinib. The goal is to see if the combination can help shrink tumors or slow cancer growth.
Houston, TexasAges 18 years+ - NCT07578571RecruitingPhase 1
Testing a New Cancer Treatment Called IM-1617
This is an early-stage study testing a new drug (IM-1617) for advanced solid cancers that have not responded to standard treatments. The drug combines an antibody with a cancer-killing agent and may help people whose cancer has progressed despite prior therapy.
Irving, TexasAges 18 years+ - NCT06526104RecruitingPhase 2
Tremelimumab and durvalumab for advanced liver cancer with Child-Pugh B
This trial tests a combination of two immunotherapy drugs, tremelimumab and durvalumab, for people with advanced liver cancer (HCC) who have moderate cirrhosis (Child-Pugh B). The goal is to see if this treatment can shrink tumors or slow cancer growth.
San Antonio, TexasAges 18 years+ - NCT06533826RecruitingPhase 2
Testing two antibody drugs for HER2-low breast cancer
This trial tests two antibody-drug conjugates (Enhertu and Datroway) for breast cancer that is HER2-low or HER2-0. It aims to find the best treatment sequence for people whose cancer has stopped responding to prior therapy.
Houston, TexasAges 18 years+ - NCT06545682RecruitingPhase 1
Study of alpelisib and pembrolizumab for advanced breast cancer or melanoma
This trial tests a combination of two drugs, alpelisib and pembrolizumab, for people with advanced triple-negative breast cancer or melanoma that has spread. The goal is to see if the combination can help shrink tumors, including those that have spread to the brain.
Houston, TexasAges 18 years+ - NCT06562543RecruitingPhase 4
Fruquintinib for advanced colorectal cancer in minority populations
This trial tests a medication called fruquintinib (an oral pill) for people with advanced colorectal cancer that has not responded to prior treatments. It is specifically looking for participants who identify as Black or African American and/or Hispanic or Latino to help understand how the drug works in these groups.
Houston, TexasAges 18 years+ - NCT06659952Recruiting
HIV+ donor hearts for HIV+ recipients
This trial tests whether hearts from donors who had HIV can be safely transplanted into people with HIV who need a heart transplant. It may offer a new option for those on the waiting list.
Dallas, TexasAges 18 years+ - NCT06695845RecruitingPhase 2
Study of zanidatamab for HER2-positive solid tumors
This trial tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein (called HER2-positive). It aims to see if zanidatamab can shrink or slow the growth of these tumors.
Amarillo, TexasAges 18 years+ - NCT06119581RecruitingPhase 3
Oloromosib with Immunotherapy as First Treatment for KRAS G12C Lung Cancer
This trial tests a new targeted pill (olomorasib) combined with immunotherapy (pembrolizumab) and possibly chemotherapy for people with advanced non-small cell lung cancer that has a KRAS G12C mutation and has not been treated before.
Austin, TexasAges 18 years+
Locally Advanced or Metastatic Solid Tumors trials by city in Texas
Where these studies are running in Texas
Institutions with a site for the recruiting locally advanced or metastatic solid tumors studies listed above.
- The University of Texas MD Anderson Cancer Center · 10 studies
- University of Texas Southwestern Medical Center · 6 studies
- Oncology Consultants · 3 studies
- Texas Oncology · 3 studies
- Texas Oncology - San Antonio · 3 studies
- Baylor College of Medicine · 2 studies
- Houston Methodist Hospital · 2 studies
- NEXT Oncology · 2 studies
What taking part in a locally advanced or metastatic solid tumors study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Locally Advanced or Metastatic Solid Tumors trials in other states
Common questions
- Are there locally advanced or metastatic solid tumors clinical trials in Texas?
- Yes. We're currently tracking 669 recruiting locally advanced or metastatic solid tumors studies with a site in Texas, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a locally advanced or metastatic solid tumors study in Texas?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Texas to take part?
- Not necessarily. These studies have a site in Texas, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a locally advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New locally advanced or metastatic solid tumors studies open in Texas regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.